Biomm S.A. (BVMF:BIOM3)

Market Cap	841.58M -32.6%
Revenue (ttm)	142.53M +16.0%
Net Income	-61.66M
EPS	-0.50
Shares Out	136.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,200
Average Volume	109,415
Open	6.12
Previous Close	6.11
Day's Range	5.97 - 6.35
52-Week Range	5.75 - 10.73
Beta	0.96
RSI	36.47
Earnings Date	May 15, 2026

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the prophylaxis and treatment ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 130
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIOM3

Financial Performance

In 2024, Biomm's revenue was 142.91 million, an increase of 20.91% compared to the previous year's 118.19 million. Losses were -77.24 million, -4.81% less than in 2023.